U.S. markets closed
  • S&P 500

    3,841.47
    -11.60 (-0.30%)
     
  • Dow 30

    30,996.98
    -179.03 (-0.57%)
     
  • Nasdaq

    13,543.06
    +12.15 (+0.09%)
     
  • Russell 2000

    2,168.76
    +27.34 (+1.28%)
     
  • Crude Oil

    51.98
    -1.15 (-2.16%)
     
  • Gold

    1,855.50
    -10.40 (-0.56%)
     
  • Silver

    25.57
    -0.29 (-1.12%)
     
  • EUR/USD

    1.2174
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.0910
    -0.0180 (-1.62%)
     
  • GBP/USD

    1.3684
    -0.0046 (-0.34%)
     
  • USD/JPY

    103.7610
    +0.2560 (+0.25%)
     
  • BTC-USD

    33,129.80
    +2,646.06 (+8.68%)
     
  • CMC Crypto 200

    651.44
    +41.45 (+6.79%)
     
  • FTSE 100

    6,695.07
    -20.35 (-0.30%)
     
  • Nikkei 225

    28,631.45
    -125.41 (-0.44%)
     

Emergency use approval for AstraZeneca COVID-19 vaccine likely in April: Slaoui

·1 min read

Dec 30 (Reuters) - The COVID-19 vaccine developed by British drugmaker AstraZeneca Plc and Oxford University will likely be authorized for emergency use in the United States in April, chief adviser for the U.S. COVID-19 vaccine program said on Wednesday.

Operation Warp Speed chief adviser Dr. Moncef Slaoui said recruitment for the British drugmaker's late-stage U.S. trial is almost complete with over 29,000 participants already enrolled.

"We project, if everything goes well with readout and emergency use authorization may be granted somewhere in April," Slaoui said. (Reporting by Mrinalika Roy in Bengaluru and Rebecca Spalding in New York; Editing by Arun Koyyur)